⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ESPR News
Esperion Therapeutics, Inc.
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
globenewswire.com
ESPR
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
globenewswire.com
ESPR
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
globenewswire.com
ESPR
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
globenewswire.com
ESPR
Form 8-K
sec.gov
ESPR
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
ESPR
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
ESPR
Form 8-K
sec.gov
ESPR
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
businesswire.com
ESPR
KKR
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
globenewswire.com
ESPR
KKR